Recce Pharmaceuticals Ltd (ASX:RCE)

Market Cap	79.91M
Revenue (ttm)	9.59M
Net Income (ttm)	-17.94M
Shares Out	262.00M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	253,912
Average Volume	192,588
Open	0.3200
Previous Close	0.3050
Day's Range	0.3100 - 0.3300
52-Week Range	0.2750 - 0.6200
Beta	0.57
RSI	45.46
Earnings Date	May 28, 2025

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. Its lead candidate is RECCE 327 (R327) for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The company also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, its product pipeline comprises R327 Intravenous, which is in Phas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RCE

Financial Performance

In 2024, Recce Pharmaceuticals's revenue was 5.03 million, an increase of 15.19% compared to the previous year's 4.37 million. Losses were -17.66 million, 35.1% more than in 2023.